Its attracted academic and government institutions by the numbers, but it needs to sign a cash lucrative royalty/partnership/licencing deal of some kind. Simple. They don't, they go bust eventually. They do....well we all know the science.
Like many I feel CEO Dr Yujing Lim is busy on all fronts encouraging innovative use of that science in more conservative areas. Like many I wonder if Mark Leong was ever the right Chair. Leong's background is allegedly South East Asian capital markets. He has done jack and if anything destroyed long-term shareholder wealth by some desperate measures to generate capital for the firm to remain a going concern. The guy has shown all the financial sway of a lollipop salesman.
That said, with A*Star, SingHealth, Zimmer Biomet, and RXcell now in arrangement with OSX, I can't help feel some partnership/collaboration interest with a much needed capital aspect might yet emerge - but I've admittedly been suggesting that for a while. That the CellHeal and Innoventure potential deals the company flagged just quietly appear to have died a death is massively disappointing.
Add to My Watchlist
What is My Watchlist?
